Pregnancy Outcomes in Chronic Myeloid Leukemia: A Single Center Experience

Irappa Madabhavi, MBBS, MD, DM1; Malay Sarkar, MD2; Mitul Modi, MD3; and Nagaveni Kadakol4

PURPOSE The aim of the current work was to report the effect of imatinib on pregnancy in patients with chronic myeloid leukemia (CML).

METHODS Data were collected between January 1998 and December 2014. One hundred four patients met inclusion criteria, and we report the results of 104 pregnancies—conceived by the participant or partner—while being on imatinib therapy for CML.

RESULTS Fifty-eight patients were male and 46 were female. Eighty-three patients, 20 patients, and one patient were had CML in the chronic phase, accelerated phase, or blast phase, respectively. Of 46 female patients, 21 underwent abortion (spontaneous, n = 36.9; elective termination, n = 8.6%). In the case of full-term pregnancy in the female partners of male patients with CML, all outcomes were uneventful. Of 46 female patients, 25 had full-term pregnancy outcomes. During the pre-imatinib era (total n = 6), patients were treated with hydroxyurea, interferon-alpha, and therapeutic leukapheresis. A total 10 of 19 pregnant patients continued on imatinib until their delivery and experienced the following outcomes: normal full-term deliveries (n = 7), preterm delivery (n = 1), omphalocele (n = 1), and craniosynostosis (n = 1). Of those who discontinued imatinib after counseling (n = 9), eight patients had full-term normal delivery, of which two patients required leukapheresis and one patient expired. All patients who continued on imatinib while pregnant were in complete cytogenetic response and major molecular response (MMR) before pregnancy, during pregnancy, and postpregnancy. Of nine patients who discontinued imatinib, two lost MMR during the third trimester and all of these patients were in complete cytogenetic response and MMR before pregnancy.

CONCLUSION It is clear that there is no standard of care for the best treatment of CML in the case of pregnancy. Interferon and/or leukapheresis will be included as treatment options. Patients can have normal pregnancies even with the administration of imatinib at the risk of congenital anomalies, intervention for which can be done after birth.

J Global Oncol. © 2019 by American Society of Clinical Oncology
Creative Commons Attribution Non-Commercial No Derivatives 4.0 License

INTRODUCTION

It has been observed that, during pregnancy, the prevalence of leukemia is less than one in 10,000 pregnancies.1 Today, for patients with chronic myeloid leukemia (CML), imatinib mesylate has become the standard therapy. If a patient wants to get pregnant, it is advisable to plan the pregnancy and to aim for a response as deep as possible, at least a major molecular response (MMR). Therapy should then be interrupted, with a preference for a 3-month washout before conception and for the duration of the pregnancy. Therapy should be resumed immediately after birth; however, if there is an unplanned pregnancy or if the patient is diagnosed while pregnant, the issue is more complicated. Although there have been some instances reported in which patients continued therapy throughout pregnancy with no problems for the baby, it is not recommend to use a tyrosine kinase inhibitor (TKI) at all during pregnancy.2 In the current study, we report the outcomes of imatinib therapy in pregnant patients or their female partners—for male patients with CML—conceived while receiving imatinib for CML.

METHODS

In this retrospective analysis from a single center in India from January 1998 to December 2014, a total of 2,008 patients with CML were treated at our center. Of 2,008 patients, 5.1% met the inclusion criteria for this study. This study was permitted by our institution review board and written informed consent was obtained from all eligible patients. Data on age, sex,
symptoms, signs, and laboratory parameters were extracted from the medical record department of our center and entered into Excel (Microsoft, Redmond, WA). From January 1998 to February 2002, patients were treated with non-TKI-based treatments, including hydroxyurea, interferon-alpha, and/or leukapheresis. After US Food and Drug Administration (FDA) approval of imatinib, most patients were treated with this TKI.

**Inclusion Criteria**
We included pregnant patients and male patients with female partners who conceived while taking imatinib who were diagnosed with Ph chromosome positive CML (CP or AP or BC) by conventional cytogenetics, fluorescence in situ hybridization (FISH) for BCR-ABL or by reverse transcript quantitative polymerase chain reaction (RT-qPCR) for BCR-ABL.

**Exclusion Criteria**
No pregnant patients were excluded.

**Assessment**
At our tertiary care center, any patients with suspected CML underwent assessment, including CBC, renal function test, liver function test, lactate dehydrogenase, serum uric acid, serum electrolytes, abdominal sonography, bone marrow aspiration, and conventional cytogenetics. If marrow cytogenetic assessment failed, then FISH or RT-qPCR was performed from peripheral blood. Immunophenotyping was performed if blast crisis was present.

**Treatment**
All pregnant patients who were taking imatinib at the time of diagnosis during the first, second, or third trimester of the conception were counseled regarding teratogenicity, toxicity, and safety data of imatinib and advised to stop imatinib and undergo therapeutic abortion if possible and, if at near term, were advised to undergo preterm delivery after consulting with an expert gynecologist. If the patient wanted to continue the pregnancy at her own risk and was not willing to undergo leukapheresis and interferon-alpha therapy, she was allowed to take imatinib at a dose of 400 mg per day. All male patients with CML were allowed to take imatinib at a dose of 400 mg per day.

Leukapheresis is offered in all three trimesters and interferon alpha is advised in second and third trimester. Hydroxyurea 25 mg/kg was continued in pre-imatinib era.

**Diagnostic Criteria for Different Phases of CML**
Peripheral blood can be used to diagnose CML. Typical indications of CML are an elevated WBC count with left shift, frequently with basophilia, and an enlarged spleen. For proper workup, a bone marrow aspiration along with cytogenetic analysis is mandatory, although FISH or polymerase chain reaction for BCR-ABL can be used to confirm the presence of BCR-ABL.

**Response Evaluation**
We used European LeukemiaNet guidelines to assess the response of imatinib and for additional monitoring of patients. Response was assessed with standardized RT-qPCR and/or cytogenetics at 3, 6, and 12 months. BCR-ABL1 transcript levels of 10% or less at 3 months, less than 1% at 6 months, and 0.1% or less from 12 months onward define optimal response, whereas levels of more than 10% at 6 months and more than 1% from 12 months onward define failure, requiring a deviation from current path of treatment. Similarly, partial cytogenetic response at 3 months and complete cytogenetic response (CCyR) from 6 months onward define optimal response, whereas no cytogenic response (Ph positive > 95%) at 3 months, less than partial cytogenetic response at 6 months, and less than CCyR from 12 months onward define failure.

**RESULTS**
Clinical characteristics of patients at presentation are as follows: Median age at presentation for males was 36 years (range, 25 to 45 years) and for females was 27 years (range, 21 to 36 years); 55.7% of patients (n = 58) were male and 44.3% (n = 46) were female. We noted common initial clinical symptoms in patients, such as generalized weakness (67.3%), heaviness of the left hypochondriac region (65.3%), abdominal pain (62.5%), fever (54.8%), and bleeding (1%). The hematologic profile of the study population is as follows: Average hemoglobin was 8.4 g/dL (range, 6 to 14 g/dL), WBC per cubic millimeter was 32,000 (range, 4,500 to 120,000/cubic mm), and platelet count per cubic millimeter was 290,000 (range, 19,000 to 940,000/cubic mm). The disease profile at presentation was CML-CP in 79.8% (n = 83), CML-AP in 19.2% (n = 20), and CML-BC in 1% (n = 1) of patients. Distribution of pregnant female patients (n = 46) according to the trimester of the pregnancy are as follows: first trimester, 45% to 6% (n = 21); second trimester, 32.6% (n = 15); and third trimester, 21.7% (n = 10). Of 46 female patients, 21 patients underwent therapeutic abortion (Table 1).

**Outcomes in Male Patients**
Outcomes of full-term pregnancy in female partners of male patients with CML were uneventful and without any congenital malformations to infants.

**Outcomes in Female Patients**
Of 46 female patients, 25 had full-term pregnancy outcomes. During the pre-imatinib era, of six patients, three were treated with hydroxyurea, interferon alpha (n = 1), and/or therapeutic leukapheresis (n = 2), and all patients had normal full-term deliveries without any complications. Nineteen pregnant patients were receiving imatinib at the time of enrollment and were counseled regarding the safety of the drug and advised to discontinue. Even after proper counseling, 10 of 19 patients continued imatinib until the time of delivery. Of 10 patients, seven had normal full-term
delivery, there was one preterm delivery, one with omphalocele, and another infant had craniosynostosis. Of those who discontinued imatinib (n = 9), eight patients had full-term normal delivery, of which two patients required leukapheresis. One patient expired from multiorgan failure as a result of septic shock during the perinatal period because of postpartum sepsis, which was determined to be unrelated to CML because her hematologic profile and RT-qPCR were normal except neutrophilia with left shift. All patients who continued imatinib even after counseling while pregnant were in CCyR and MMR prepregnancy, during pregnancy, and postpregnancy (Table 2).

**Observation of Newborns**
- Newborns of male patients with CML who are receiving imatinib: All newborns (age range, newborn to 11 years old), toddlers, and children were doing well with normal development of all milestones (gross motor, fine motor, language, cognitive, social skills, vision, and hearing).
- Newborns of female patients with CML in the pre–imatinib era: All six newborns (age range, 13 to 22 years old), toddlers, and children were doing well with normal development of all milestones.
- Newborns of female patients with CML in the post–imatinib era:
  - Newborns of female CML patients who discontinued imatinib after proper counseling: All nine newborns (age range, 4 to 8 years old), toddlers, and children were doing well with normal development of all milestones.
  - Newborns of female patients with CML who continued imatinib after proper counseling: All eight newborns

### TABLE 1. Landmark Studies of Imatinib in Pregnant Patients With CML

| First Author | Year | No. | Conclusion |
|--------------|------|-----|------------|
| Ault et al14 | 2005 | 19 (female, n = 10; male, n = 8) | There is no evidence that a short exposure to imatinib during conception and pregnancy negatively affects the developing fetus |
| Pye et al32  | 2008 | 180 | Most patients lose their response after interruption of imatinib |
| Pye et al32  | 2008 | 180 | Patients receiving imatinib should take efficient contraception |
| Nomura et al33| 2011 | 9 | Outcomes were accessible for 125 patients (69%), of which 50% delivered normal infants and 28% underwent optional terminations, three of which followed the identification of abnormalities, and 14% had a miscarriage |
| Alizadeh et al34 | 2014 | 22 (female, n = 9; male, n = 5) | Although most pregnancies exposed to imatinib are likely to have a successful result, there remains a risk that exposure may result in grave fetal malformations |
| Zhou et al22 | 2013 | 25 (female, n = 18; male, n = 7) | Of nine patients, four were treated with imatinib when they became pregnant, with treatment being interrupted in the first trimester in three patients and in the second trimester in one |
| Alizadeh et al34 | 2014 | 22 (female, n = 9; male, n = 5) | During pregnancy, three patients (33.3%) required no chemotherapy after discontinuation of imatinib, and six (66.7%) were treated with interferon (n = 5) and/or hydroxyurea (n = 3). |
| Zhou et al22 | 2013 | 25 (female, n = 18; male, n = 7) | The mean gestational age at delivery was 37.6 weeks and the mean birth weight was 2,870 g in CML-associated pregnancies |
| Iqbal et al35 | 2014 | 90 (female, n = 21; male, n = 40) | The authors concluded that female patients should use contraceptives with no such requirements in male patients |
| Alizadeh et al34 | 2014 | 22 (female, n = 9; male, n = 5) | Despite exposure of either partner to imatinib, parents can most likely expect an uneventful outcome to a pregnancy |
| Zhou et al22 | 2013 | 25 (female, n = 18; male, n = 7) | All seven male patients had normal pregnancies |
| Iqbal et al35 | 2014 | 90 (female, n = 21; male, n = 40) | In female patients, eight had elective abortion, three had spontaneous abortion, and seven passed to term, resulting in the birth of eight healthy babies |
| Zhou et al22 | 2013 | 25 (female, n = 18; male, n = 7) | The authors concluded that female patients should use contraceptives with no such requirements in male patients |
| Iqbal et al35 | 2014 | 90 (female, n = 21; male, n = 40) | Twenty-eight pregnancies occurred in female patients, whereas 62 were from male patients |

Abbreviation: CML, chronic myeloid leukemia.
| Treatment                                                                 | No.  | Response       | Outcome of Pregnancy                                                                 |
|--------------------------------------------------------------------------|------|----------------|--------------------------------------------------------------------------------------|
| Female partners of the male patients with CML on imatinib or hydroxy urea| 58   | Not applicable | All female partners of the patients with CML had normal full-term deliveries without any congenital malformations |
| Abortions:                                                               | 21   | Not applicable | Not applicable                                                                      |
| - Spontaneous                                                            | 17   |                |                                                                                      |
| - Elective termination                                                   | 4    |                |                                                                                      |
| Full-term pregnancy:                                                    | 25   |                |                                                                                      |
| Pre-imatinib era:                                                       | 6    |                |                                                                                      |
| Patient required hydroxy urea (n = 3)/ interferon alpha (n = 1)/therapeutic leukapheresis (n = 2) | 6    | Records are not available for RT-PCR and FISH | All six patients had normal full-term delivery without any congenital malformations |
| Imatinib era:                                                           | 19   |                |                                                                                      |
| All patients were in CCyR and MMR prepregnancy, during pregnancy, and postpregnancy | 19   |                |                                                                                      |
| Patients continued imatinib even after counseling                        | 10   |                | Seven normal full term delivery, 1 preterm delivery, and 2 congenital malformations (omphalocele, n = 1; craniosynostosis, n = 1) |
| Patients discontinued imatinib after counseling                          | 9    |                | Eight patients had full-term normal delivery, of which 2 patients required leukapheresis, and 1 patient expired during perinatal period because of sepsis |

Abbreviations: CCyR, complete cytogenic response; CML, chronic myeloid leukemia; FISH, fluorescence in situ hybridization; MMR, major molecular response; RT-PCR, reverse-transcription polymerase chain reaction.
(age range, 4 to 8 years old), toddlers, and children were doing well with normal development of all milestones.

- Newborn with omphalocele: Primary surgical repair was performed on the second day of the neonatal period. The child had manageable feeding problems and was doing well. He is now 6 years old studying at the first standard.
- Newborn with craniosynostosis: The newborn was having scaphocephaly, and total cranial vault remodeling intervention was performed at the fifth month of infancy. The child is now 2.5 years old with normal milestone development to date.

Recommendations for Female Patients With CML Receiving Imatinib and Planning Pregnancy or Diagnosed With CML During Pregnancy

Figures 1 and 2 show suggested algorithms for the management of pregnancy in patients with CML who are on treatment with imatinib with unplanned pregnancy or diagnosis of CML in pregnancy (Fig 1), and who are on treatment with imatinib and planning an elective pregnancy or planned pregnancy (Fig 2). Generally, RT-qPCR increases if the patient is taken off treatment, but this increase does not necessitate the treatment to be intervened. When the patient is taken off treatment, the first measurement should be performed after 2 to 3 three months. However, the frequency of additional monitoring will be decided by the rate at which the full blood count of the patient increases initially and RT-qPCR. Another treatment approach that considers leukemic burden and pregnancy terms may be helpful for avoiding interventions in treatment in the case of favorable situations and takes into account the interests of both the child and mother when treatment initiation becomes necessary. For female patients with CML, this treatment approach can significantly increase the chances of having children. Even so, both the patient and physician should understand the possible risks. Managing CML at pregnancy with huge leukemic mass is still a complicated task; pregnancy with CML should be

**FIG 1.** Suggested algorithm for management of pregnancy in patients with chronic myeloid leukemia (CML) who are on treatment with imatinib with unplanned pregnancy or diagnosis of CML in pregnancy. IFN-α, interferon alpha; TKI, tyrosine kinase inhibitor; WCC, white cell count.
thoroughly planned at deep remission. In patients with less than 15 weeks of gestation, TKIs should be stopped and patients should be observed without treatment. After 15 weeks of gestation, if BCR-ABL is less than 1% we can observe without any treatment, and if BCR-ABL is more than 1% we can restart therapy with imatinib, nilotinib, and no dasatinib.

DISCUSSION
The most common malignancies associated with pregnancy are cervical cancer, breast cancer, melanoma, lymphomas, and acute leukemia. CML presents as approximately 10% cases of pregnancy-associated leukemia. CML in pregnancy is not associated with an increase in premature infants, low birth weight, or abortion rates, which were concerns previously. The disease course is akin to that in nonpregnant females.

Management options for CML diagnosed in pregnancy are imatinib, hydroxyurea, interferon alfa, and leukapheresis. During the pre–imatinib era, literature has revealed reasonably varied facts regarding hydroxyurea, but not enough to be endorsed by the FDA. Hydroxyurea was used as a cytotoxic agent before the discovery of TKI and has been documented to cause fetal growth restriction, intrauterine death, and craniofacial and spinal defects. Cytotoxic chemotherapy, such as busulphan, is significantly associated with fetal malformations. Interferon alpha works slowly but the FDA has approved interferon alpha as category C during pregnancy. There are several case series that have demonstrated that leukapheresis may be considered a safe procedure in situations when protection of the fetus is preferred, mainly during hyperleukocytosis. As compelling data do not exist at present, use of TKIs and other cytotoxic agents could not be suggested for regular use. Interferon alpha has a higher molecular weight—unable to cross the placenta—and does not inhibit DNA synthesis. Hence, it is considered safe in pregnancy.

Imatinib has changed a mortal disease with a median survival of 6 to 7 years into a chronic condition for a large number of patients. Apart from inhibiting the BCR-ABL1 protein, TKIs also reduce stem-cell factor (c-kit), platelet-derived growth factor receptors, arg, c-fms, and src—especially by dasatinib—proteins, which are pertinent to implantation, fetal maturation, and gonadal development, at least revealed by animal studies.

Imatinib in Men
There is no increased jeopardy of congenital malformations or increased abortion with usual and higher doses of
Imatinib resulted in teratogenicity in mice. Newer studies have shown that imatinib exposure leads to a significant decline in testosterone levels in adult patients with CML; however, outcomes of pregnancy in more than 150 patients were uneventful, excluding the malrotation of the intestine and single stillbirth with malformations. An imatinib-treated patient with hyper eosinophilic syndrome developed oligospermia. No special safety measures are relevant for male patients receiving TKIs.

**Imatinib in Women**

Imatinib use in pregnancy comes under category D according to FDA. Women should be well informed about the impending danger to the fetus if used during pregnancy or if the patient becomes pregnant while taking this drug. It is recommended that female patients follow adequate contraception. With imatinib, the majority of patients achieve deep, long-lasting responses, which is associated with normal life expectancy. Mammalian ovaries express c-kit, c-abl, and platelet-derived growth factor, which are inhibited by TKI, that are imperative in the growth and maturity of oocytes and follicles. When CML is diagnosed in the first trimester, termination of pregnancy is considered harmless for the mother; however, TKIs are associated with fetal malformations if used in the second trimester. Platelet-derived growth factor A inhibition of imatinib resulted in teratogenicity in mice.

Distinguishing congenital abnormalities have occurred after the administration of imatinib in early pregnancy. These include exomphalos, omphaloceles, pulmonary hypoplasia, duplex kidneys, renal agenesis, skeletal malformations (craniosynostosis, shoulder anomaly, and scoliosis), and spontaneous abortion. The incidence of exomphalos is approximately 100-fold greater than predictable. Once pregnancy has been documented, if the patient is receiving imatinib it should be stopped. Close monitoring of fetal growth, especially a nuchal scan, should be performed for fetal anomalies. No trial has demonstrated cumulative toxicity of imatinib and fetal malformations. Cole et al studied the cases of 215 women who became pregnant while taking imatinib until 2009. Of 215 women, 171 sustained their pregnancy to term—62 of them had unknown outcomes, whereas 109 pregnancies had known outcomes: 33% (n = 36) had complications, such as spontaneous abortion (n = 24), stillbirth (n = 1), malformations (n = 9), and low birth weight (n = 2). Imatinib does not have any effect on folliculogenesis or spermatogenesis. Until now, the number of cases of pregnant women with CML reported in the literature is more than 200; however, with the exception of imatinib, there are no data available on the use of targeted agents nor various landmark studies of imatinib in pregnant patients with CML (Table 1).

**Second-Generation TKI During Pregnancy**

Nilotinib for men: Little has been reported regarding conception during nilotinib treatment. Nilotinib for women: As for men, little has been reported for women who become pregnant while being treated with nilotinib. One patient at the 3-month ultrasound showed a large omphalocele, which resulted in the pregnancy interruption, and another patient’s fetus was exposed to nilotinib for 5 weeks before stopping therapy and pregnancy was unremarkable, with the delivery of a healthy girl. Dasatinib for men: Cortes et al studied the effects of dasatinib on pregnant partners of nine male patients who conceived children while receiving dasatinib. Of these patients, one mother experienced preeclampsia but eventually delivered a healthy baby at 37 weeks, free of any birth defects or neonatal complications. Dasatinib for women: To study the effect of dasatinib on pregnant women, 13 pregnant patients were observed. Of these patients, only one normal newborn was delivered; one patient gave birth to a premature newborn, four women had to undergo induced abortions, another two had spontaneous abortions, and five women were pregnant at last reported follow-up. In conclusion, temporarily discontinuing TKIs nilotinib and dasatinib, then observing or intervening with interferon alpha and or leukapheresis, can be considered to be the safest and thus the best potential therapeutic options for the management of CML in pregnancy.

Other TKIs: No conceptions/pregnancies have been reported while receiving ponatinib.

**Breast Feeding**

Imatinib and its active metabolite are excreted into human milk.

**Future Perspectives**

Some stopping imatinib studies (TWISTER [A phase II study to determine relapse-free interval after withdrawal of imatinib therapy in adult patients with chronic phase chronic myeloid leukaemia in stable complete molecular remission] and STIM [Stop Imatinib] trials) have demonstrated that even after discontinuing imatinib and attaining complete molecular response for 2 years, nearly 40% of patients maintain a deep response with undetectable BCR-ABL1 transcripts. On the basis of existing data, female patients with CML who have a desire become pregnant should be advised to wait until persistent MMR is achieved for a minimum of 2 years with monitoring of CBC and RT-qPCR. For future assisted conception in patients who at least achieve complete hematologic response and who plan for future pregnancy, it is advised to collect oocytes. Start in vitro fertilization drugs 7 days after stopping TKI and resume TKI after the oocytes collection (Table 4).

**Impact of Imatinib and Other 2G-TKIs on Pregnancy in Patients With CML**

Physiologic changes, which also include changes in hematologic parameters accompanying pregnancy, may
### TABLE 3. CML in Pregnancy Outcomes After 2G-Tyrosine Kinase Inhibitor Therapy

| CML | First Trimester | Outcome |
|-----|----------------|---------|
| **Dasatinib (n = 4)** | n = 1<sup>38</sup> | Fetal hydrops and cytopenias |
|  | n = 1 (5/40 weeks)<sup>39</sup> | Normal pregnancy, induction of labor |
|  | n = 1 (4/40 weeks)<sup>40</sup> | Normal pregnancy, LSCS at 33 weeks |
|  | n = 1 (6/40 weeks)<sup>41</sup> | Normal pregnancy, SVD at 37/40 weeks |
| **Dasatinib<sup>46</sup> (n = 8)** | TOP, n = 3; SA, n = 2 (8/40 and 9/40) | Deliveries, n = 3; normal infant, n = 1 LSCS at 7 months, small for dates |
|  | Normal pregnancy at 21 weeks | Outcome unknown |
| **Dasatinib<sup>47</sup> (n = 13 of 17)** | n = 1 normal newborn | |
|  | n = 1 premature newborn | |
|  | n = 4 induced abortion | |
|  | n = 2 spontaneous abortion | |
| **Dasatinib<sup>48</sup> (n = 2)** | 5-8/38 weeks | Normal pregnancy and both delivered at 38 weeks |
| **Dasatinib<sup>49</sup> (n = 46)** | n = 15 healthy live births | |
|  | n = 8 abnormal infants | |
|  | n = 18 elective abortion | |
|  | n = 7 fetal and infantile complications | |
| **Dasatinib in men<sup>50</sup> (n = 9)** | n = 7 normal newborns | |
|  | n = 1 one mother experienced preeclampsia | |
|  | n = 2 outcomes unknown | |
| **Nilotinib<sup>57</sup>** | 8/40 weeks | Normal pregnancy LSCS at 33 weeks |
| **Nilotinib<sup>58</sup>** | 5-9/38 weeks | Normal pregnancy and delivered female twins at 38 weeks |
| **Nilotinib<sup>59</sup>** | 11/37 weeks | Normal pregnancy LSCS at 37th week |
| **Nilotinib<sup>60</sup>** | 7.4/38 weeks | Normal pregnancy, delivery at 38 weeks |
| **Nilotinib<sup>61</sup>** | 9/10.2 weeks | Miscarriage at 10.2 weeks |
| **Nilotinib<sup>62</sup> (n = 2; 1 patient twice conceived)** | 16/38 weeks | Normal baby by LSCS |
|  | 7.4/33 weeks | Normal baby by LSCS |
|  | 5 weeks | Big omphalocele, pregnancy interrupted |
| **Nilotinib<sup>63</sup> (n = 1)** | 5/38 weeks | Healthy female baby |
|  | n = 1 fetal abnormality | |
|  | n = 1 twins, one baby died because of congenital transposition of great vessels, and another one with nonserious heart murmur | |
|  | n = 43 healthy babies | |
| **Nilotinib in men<sup>64</sup> (n = 1)** | Healthy baby | |
| **Nilotinib in men<sup>65</sup> (n = 36)** | n = 35 healthy babies | |
|  | n = 1 therapeutic abortion because of fetal abnormality | |
| **Bosutinib<sup>67</sup> (n = 33)** | n = 8 vaginal deliveries of healthy babies | |
| **Father exposure (n = 17)** | n = 1 LSCS healthy baby | |
|  | n = 4 induced abortion | |
|  | n = 1 spontaneous abortion | |
|  | n = 3 unknown outcomes | |

(Continued on following page)
complicate the diagnosis of CML during pregnancy as they may mask the symptoms.

As the prothrombotic proteins and hemostatic factors increase physiologically, and the venous blood flow is obstructed physically, the prothrombotic potential of a normal pregnancy is recognized. Hence, it is clear that thrombosis can be considered to be the most common cause of maternal morbidity. In the case of myeloproliferative diseases, this may be compounded where there is an associated increase in blood platelet count.5,13

All TKIs have similar class effects as they inhibit BCR-ABL1. TKIs also have a lot of off-target effects as a result of the inhibition of c-kit, platelet-derived growth factor receptors, arg, and c-fms. Furthermore, it should be noted that one of the 2G-TKIs, dasatinib, also inhibits src and related proteins, which are relevant to gonadal development, embryonic implantation, and fetal maturation.5,13

Less experience has been reported with 2G-TKIs36-42 (Table 3; bosutinib, dasatinib, nilotinib, and ponatinib) in pregnancy. Dual BCR-ABL/src kinase inhibitor dasatinib crosses the placenta and results in considerable levels of fetal plasma. It has been reported that, in the first trimester, dasatinib causes fetal hydrops and severe fetal bicytopenia; however, there have been reports of some pregnancies as well.

In conclusion, the management of CML during pregnancy poses a therapeutic dilemma because of the potential teratogenic effect of therapy and requires the contemplation of both maternal and fetal life. Imatinib use during pregnancy is a double-edged sword, because discontinuation of the drug is associated with a loss of cytogenetic and molecular response, as well as consequences of the disease and, if

| TABLE 3. CML in Pregnancy Outcomes After 2G-Tyrosine Kinase Inhibitor Therapy (Continued) |
|---------------------------------------------------------------|
| **CML** | **First Trimester** | **Outcome** |
| Maternal exposure (n = 16) | n = 5 vaginal deliveries of healthy babies | |
| | n = 1 partial molar pregnancy | |
| | n = 1 baby delivered, data not known | |
| | n = 2 induced abortion | |
| | n = 1 spontaneous abortion | |
| | n = 6 unknown outcomes | |

Abbreviations: CML, chronic myeloid leukemia; LSCS, lower-segment cesarean section; SA, spontaneous abortion; SVD, single vaginal delivery; TOP, termination of pregnancy.

| TABLE 4. Management of a Female Patient With CML Planning a Pregnancy |
|---------------------------------------------------------------|
| **Preconception** | > 18-24 months stable > MMR |
| | Counseling with an ob/gyn to check on: |
| | Fertility |
| | Routine preconception tests |
| | Monitor ovulation |
| **TKI interruption** | Interruption of TKI can be done 7-10 days after ovulation (before implant) |
| | Absolutely no TKI therapy between 5 and 13 weeks or 31 and 71 days after the last menstrual cycle (organogenesis) |
| | If available, get in touch with the team that will follow the pregnancy-delivery (hematologist, ob/gyn, neonatologist) |
| **Disease monitoring** | Blood counts according to pregnancy follow-up |
| | Q-PCR every month if no 4.5 CMR* |
| | Q-PCR every 2 months if CMR |
| | In the case of loss response, always consider the risk to the mother and baby; consider treatment if loss of MMR/CCR |
| | Restart treatment if there is a loss of hematologic response |
| **Post delivery** | Breast feed the first 2-5 days to give the child colostrum; if in MMR/CCR consider continuing breast feeding depending on PCR results |
| | Restart treatment with the same TKI used before |

Abbreviations: CCR, complete cytogenetic response; CML, chronic myeloid leukemia; CMR, complete molecular response; MMR, major molecular response; Q-PCR, quantitative polymerase chain reaction; TKI, tyrosine kinase inhibitor.

*4.5 CMR corresponds to a BCR-ABL transcript of ≤ 0.0032% copies.
continued, results in fetal jeopardy. Several treatment approaches have been used for CML with pregnancy, including hydroxyurea, leukapheresis, and interferon alpha. There are various adverse pregnancy outcomes with TKIs, such as spontaneous abortion, miscarriage, stillbirth, preterm delivery, and malformed child. The various malformations of TKIs are omphalocele, craniosynostosis, clinodactyly, short fifth fingers, slightly downward slanting palpebral fissures, renal and vertebral anomalies, as in our case (right renal agenesis and hemivertebrae), and low birth weight.

REFERENCES
1. Pentheroudakis G, Orecchia R, Hoeckstra HJ, et al: Cancer, fertility and pregnancy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(suppl. 5):v266-v273, 2010
2. Cortes J, Kantarjian H: How I treat newly diagnosed chronic phase CML. Blood 120:1390-1397, 2012
3. Pentheroudakis G, Orecchia R, Hoeckstra HJ, et al: Cancer, fertility and pregnancy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21:v266-v273, 2010 (suppl 5)
4. Apperley J: CML in pregnancy and childhood. Best Pract Res Clin Haematol 22:455-474, 2009
5. Milojkovic D, Apperley J: State-of-the-art in the treatment of chronic myeloid leukaemia. Curr Opin Oncol 20:112-121, 2008
6. Fadliah SA, Ahmad-Zailani H, Soon-Keng C, et al: Successful treatment of chronic myeloid leukemia during pregnancy with hydroxyurea. Leukemia 16:1202-1203, 2002
7. Harrison C: Pregnancy and its management in the Philadelphia negative myeloproliferative diseases. Br J Haematol 129:293-306, 2005
8. Thauvin-Robinet C, Maingueneau C, Robert E, et al: Exposure to hydroxyurea during pregnancy: A case series. Leukemia 15:1309-1311, 2001
9. Breccia M, Cannella L, Montefusco E, et al: Male patients with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies. Report of five cases. Leuk Res 32:519-520, 2008
10. Apperley J, Pye S: Chapter 19: The haematological malignancies, in Kehoe S, Jauniaux E, Martin-Hirsch P, et al (eds) Cancer and Reproductive Health. London, United Kingdom, RCOG Press, pp 243-256, 2008
11. Ströbl FJ, Voelkerding KV, Smith EP: Management of chronic myeloid leukemia during pregnancy with leukapheresis. J Clin Apher 14:42-44, 1999
12. Yazdani Brojeni P, Matok I, Garcia Bournissen F, et al: A systematic review of the fetal safety of interferon alpha. Reprod Toxicol 33:265-268, 2012
13. Strobl FJ, Voelkerding KV, Smith EP: Management of chronic myeloid leukemia during pregnancy with leukapheresis. J Clin Apher 14:42-44, 1999
14. Ault P, Kantarjian H, O’Brien S, et al: Adult reproductive functions after early postnatal inhibition by imatinib of the two receptor tyrosine kinases, c-kit and PDGFR, in the rat testis. Reprod Toxicol 25:442-446, 2008
15. Hensley ML, Ford JM: Imatinib treatment: Specific issues related to safety, fertility, and pregnancy. Semin Hematol 40 (suppl 2) 21-25, 2003
16. Ramasamy K, Hayden J, Lim Z, et al: Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy. Br J Haematol 137:374-375, 2007
17. Baker MA, Hetherington L, Curry B, et al: Phosphorylation and consequent stimulation of the tyrosine kinase c-Abl by PKA in mouse spermaotzoa; its implications during capacitation. Dev Biol 333:57-66, 2009
18. Ghalaut VS, Prakash G, Bansal P, et al: Effect of imatinib on male reproductive hormones in BCR-ABL positive CML patients: A preliminary report. J Oncol Pharm Pract 20:243-248, 2014
19. Bay K, Bjernum OW, Olsson-Strömberg U, et al: Reproductive hormone profiles during imatinib therapy in men with chronic myeloid leukemia. Andrology 2:2167-0250, 2013
20. Abruzzese E, Trawinska MM, Perrotti AP, et al: Tyrosine kinase inhibitors and pregnancy. Mediterr J Hematol Infect Dis 6:e2014028, 2014

ACKNOWLEDGMENTS
The authors thank Nagaveni Irappa Madabhavi (lecturer, Government Polytechnic Zalaki, Bijapur, Karnataka, India) for drawing the figures.
CML in Pregnancy: An Indian Experience

21. Seshadri T, Seymour JF, McArthur GA: Oligospermia in a patient receiving imatinib therapy for the hypereosinophilic syndrome. N Engl J Med 351:2134-2135, 2004
22. Zhou L, You JH, Wu W, et al: Pregnanacies in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitor. Leuk Res 37:1216-1221, 2013
23. Christopoulos C, Dimakopoulou V, Rotas E: Primary ovarian insufficiency associated with imatinib therapy. N Engl J Med 398:1079-1080, 2008
24. Schmandt RE, Broaddus R, Lu KH, et al: Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer 98:758-764, 2003
25. Hutt KJ, McLaughlin EA, Holland MK: Kit ligand and c-KIT have diverse roles during mammalian oogenesis and folliculogenesis. Mol Hum Reprod 12:61-69, 2006
26. Garderet L, Santacruz R, Barbuj V, et al: Two successful pregnancies in a chronic myeloid leukemia patient treated with imatinib. Haematologica 92:e9-e10, 2007
27. Cole S, Kantarjian H, Ault P, et al: Successful completion of pregnancy in a patient with chronic myeloid leukemia without active intervention: A case report and review of the literature. Clin Lymphoma Myeloma 9:324-327, 2009
28. Schultheis B, Nijmeijer BA, Yin H, et al: Imatinib mesylate at therapeutic doses has no impact on folliculogenesis or spermatogenesis in a leukaemic mouse model. Leuk Res 36:271-274, 2012
29. Barkoulas T, Hall PD: Experience with dasatinib and nilotinib use in pregnancy. J Oncol Pharm Pract 24:121-128, 2018
30. Ross DM, Branford S, Seymor JF, et al: Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: Results from the TWISTER study. Blood 122:515-522, 2013
30a. Cortes J, O’Brien S, Ault P, et al: Pregnancy outcomes among patients with chronic myeloid leukemia treated with dasatinib. Blood (abstr 3230). Poster presented at the 50th American Society of Hematology Annual Meeting; December 6–9, 2008; San Francisco, CA
31. Mahon FX, Rêa D, Guilhot J, et al: Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11:1029-1035, 2010
32. Pye SM, Cortes J, Ault P, et al: The effects of imatinib on pregnancy outcome. Blood 111:5505-5508, 2008
33. Nomura RM, Igi AM, Faciori NC, et al: Maternal and perinatal outcomes in pregnant women with leukemia (in Portuguese). Rev Bras Ginecol Obstet 33:174-181, 2011
34. Alizadeh H, Jaafar H, Rajnics P, et al: Outcome of pregnancy in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Short report from a single centre. Leuk Res 39:47-51, 2015
35. Iqbal J, Ali Z, Khan AU, et al: Pregnancy outcomes in patients with chronic myeloid leukemia treated with imatinib mesylate: Short report from a developing country. Leuk Lymphoma 55:2109-2113, 2014
36. Cortes J, O’Brien S, Ault P, et al: Pregnancy outcomes among patients with chronic myeloid leukemia treated with dasatinib. Blood 112:3230, 2008 (abstr)
37. Conchon M, Sanabani SS, Bendit I, et al: Two successful pregnancies in a woman with chronic myeloid leukemia exposed to nilotinib during the first trimester of her second pregnancy: Case study. J Hematol Oncol 2:42, 2009
38. Berveiller P, Andreoli A, Mir O, et al: A dramatic fetal outcome following transplacental transfer of dasatinib. Antcancer Drugs 23:754-757, 2012
39. Kroll T, Ames MB, Prueett JA, et al: Successful management of pregnancy occurring in a patient with chronic myeloid leukemia on dasatinib therapy. Leuk Lymphoma 51:1751-1753, 2010
40. Conchon M, Sanabani SS, Serpa M, et al: Successful pregnancy and delivery in a patient with chronic myeloid leukemia while on dasatinib therapy. Adv Hematol 2010:136252, 2010
41. Bayraktar S, Morency B, Escalon MP: Successful pregnancy in a patient with chronic myeloid leukemia exposed to dasatinib during the first trimester. BMJ Case Rep 2010:bcr0520102975, 2010
42. He K, Lago MW, Iyer RA, et al: Lacteal secretion, fetal and maternal tissue distribution of dasatinib in rats. Drug Metab Dispos 36:2564-2570, 2008
43. Hadiji Mseddi S, Kallel F, Amouri H, et al: Delivery of two normal twins exposed to imatinib and nilotinib during the first trimester of pregnancy: A single case. J Hematol Oncol 2:42, 2009
44. Fadhilla R, Ardiansyah IR, Sucipto MCR, et al: A case study: Exposure of nilotinib in pregnancy with chronic myeloid leukemia: Is it safe? ESMO Asia Congress, Singapore, December 18, 2016
45. Sweany SJ: TKIs and the treatment of CML in pregnant women. HemOnc Today, October 25, 2011. https://www.healio.com/hematology-oncology/leukemia/news/print/hemonc-today/%7Bff202790-727e-43aa-9d19-403b622c670%7D/tkis-and-the-treatment-of-cml-in-pregnant-women
46. Arnall J, Mulunehe B: Loss of pregnancy in a patient with chronic myeloid leukemia during treatment with nilotinib. J Hematol Oncol Pharm 6:22-27, 2016
47. Cortes JE, Gambacorti-Passerini C, Deininger MW, et al: Pregnancy outcomes in patients treated with bosutinib. Blood 132:1729, 2018 (abstr)
48. Cortes JE, Abuzzese E, Chelysheva E, et al: The impact of dasatinib on pregnancy outcomes. Am J Hematol 90:1111-1115, 2015
49. Cortes J, O’Brien S, Ault P, et al: Pregnancy outcomes among patients with chronic myeloid leukemia treated with dasatinib. Blood 112:3230, 2008 (abstr)